NasdaqGS:ACADBiotechs
Is It Time To Reconsider ACADIA Pharmaceuticals (ACAD) After Strong One Year Share Price Gain?
If you are trying to figure out whether ACADIA Pharmaceuticals is priced attractively right now, you are in the right place.
The stock recently closed at US$26.13, with returns of 41.2% over 1 year, 31.6% over 3 years and a 49.0% decline over 5 years. Shorter term moves of 2.7% over 7 days and 0.6% over 30 days show a quieter near term picture.
Recent news around ACADIA has focused on its position within the pharmaceuticals and biotech space and investor interest in how its product pipeline...